In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-05702-0
Abstract: Although checkpoint inhibitors (CPIs) have changed the paradigm of cancer therapy, low response rates and serious systemic adverse events remain challenging. In situ vaccine (ISV), intratumoral injection of immunomodulators that stimulate innate immunity at the… read more here.
Keywords: response; local immunotherapy; spg; tlr9 ligand ... See more keywords
Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2116738119
Abstract: Significance Harnessing the heterogeneity of the cancer antigenic landscape to induce antitumor T cells is at the basis of personalized vaccines and adoptive T cell–transfer therapies. However, these highly personalized approaches remain associated with limited… read more here.
Keywords: immunity local; anti cytomegalovirus; local immunotherapy; solid tumors ... See more keywords